智通财经APP获悉，得益于强劲的假日购物季消费带动，加拿大电商平台Shopify(SHOP.US)第四季度业 绩超出市场预期。财报显示，Shopify第四季度营收同比增长31%至37亿美元，好于分析师平均预期的36 亿美元;衡量平台交易规模的商品交易总额(GMV)接近1240亿美元，同样超出分析师预期，显示消费者 支出持续强劲。营业利润为6.31亿美元，高于分析师平均预期的5.88亿美元;净利润则从上年同期的12.9 亿美元降至7.43亿美元。截至发稿，Shopify周三美股盘前涨超11%。 尽管美国总统特朗普加征关税引发的经济冲击、生活成本上升挑战以及劳动力市场担忧持续挤压购物预 算，但在高收入家庭主导的驱动下，美国消费者支出依然保持强劲。美国去年10月和11月消费者支出亦 稳健增长，为零售商假日季度销售提供支撑。Shopify的增长因此获得动力，该公司主要通过支付处理 费用从商家销售额中抽成以及向商家销售订阅计划获得收入。 声明指出，2025年是Shopify全速推进的一年，公司在实现复合增长的同时，正为人工智能(AI)电商新时 代铺设轨道。该公司首席财务官杰夫·霍夫迈斯特表示："随着人工智能重塑买家发现 ...

Core Insights - GoodRx Holdings, Inc. (GDRX) reported revenue of $203.07 million for the quarter ended June 2025, reflecting a 1.2% increase year-over-year, while EPS was $0.09, up from $0.08 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $205.18 million, resulting in a surprise of -1.03%, and the EPS also missed the consensus estimate of $0.10 by 10% [1] Financial Performance Metrics - Monthly Active Consumers stood at 6, matching the average estimate from three analysts [4] - Subscription plans totaled 668, slightly below the two-analyst average estimate of 677 [4] - Revenue from prescription transactions was $143.06 million, which was lower than the estimated $148.77 million, marking a -2.5% change year-over-year [4] - Revenue from other sources was $4.56 million, compared to the average estimate of $4.63 million, representing a -15.5% year-over-year change [4] - Revenue from pharma manufacturer solutions reached $34.98 million, exceeding the average estimate of $31.54 million, showing a +32% year-over-year increase [4] - Subscription revenue was reported at $20.46 million, below the estimated $20.93 million, reflecting a -7% change compared to the previous year [4] Stock Performance - GoodRx shares have declined by -9.3% over the past month, contrasting with a +0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]